Better Therapeutics And Glooko Announce Partnership To Accelerate Adoption Of Aspyrerx To Treat Type 2 Diabetes In The United States

By Author: James Colin
Total Articles: 117
Comment this article

A strategic agreement has been established by Better Therapeutics Inc. (NASDAQ: BTTX) and Glooko, Inc. to include Better Therapeutics' AspyreRxTM digital behavioral treatment for type 2 diabetes (T2D) into Glooko's diabetes management platform. While Glooko is a world leader in the management of chronic conditions, Better Therapeutics is acknowledged as a pioneer in the development of prescription digital therapeutics (PDTs) for the treatment of cardiometabolic disorders.

Through this partnership, healthcare professionals in the US who utilize the Glooko platform will be able to find patients who would benefit from AspyreRx, make prescriptions easier, and keep an eye on patients as they progress through their course of treatment. Over 3.4 million Americans with diabetes have benefited from Glooko's diabetes management solutions, which are used in close to 5,000 clinic locations.

In the United States, AspyreRx will be incorporated into the Glooko healthcare provider (HCP) platform, providing healthcare professionals with an additional treatment choice and increasing the tools at their disposal for patient ...
... population management. By utilizing Glooko's 'precision engagement' feature, the platform will determine which patients are good candidates for AspyreRx, making it easier for the healthcare provider to give this cutting-edge medication.

Glooko CEO Russ Johannesson was enthusiastic about the collaboration, saying, "We are thrilled to work with Better Therapeutics to bring AspyreRx to the Glooko platform. Through this collaboration, healthcare practitioners in the Glooko network will have easier access to a significant new treatment option, improving their ability to manage patient populations and improve the health of T2D patients."

Better Therapeutics CEO Frank Karbe emphasized that Glooko is a perfect partner for driving AspyreRx adoption, pointing to the wide overlap between AspyreRx early adopters and providers utilizing the Glooko platform. He also underlined how Glooko's precise engagement might hasten patients' access to AspyreRx, a cutting-edge new medication, if they qualify for it.

Better therapies is a company that specializes in creating innovative prescription digital therapies that use cognitive behavioral therapy (CBT) to address the underlying causes of or exacerbations of cardiometabolic disorders. The company's exclusive platform is dedicated to creating software-based, FDA-regulated treatments for heart disease, type 2 diabetes, and other ailments. Better Therapeutics' PDTs administer CBT with the goal of altering brain pathways to facilitate long-lasting behavioral changes that may improve patient outcomes while lowering medical expenses. Better Therapeutics has produced clinically verified mobile applications that are meant to be prescribed by doctors and paid for similarly to traditional pharmaceuticals.

In conclusion, Better Therapeutics and Glooko's collaboration is set to improve diabetes care by incorporating AspyreRx into the Glooko platform. Through this partnership, Glooko's vast network of support for millions of people with diabetes is leveraged, offering healthcare providers a cutting-edge treatment option to enhance patient outcomes across the country.

Read More: https://www.techdogs.com/tech-news/business-wire/better-therapeutics-and-glooko-announce-partnership-to-accelerate-adoption-of-aspyrerx-to-treat-type-2-diabetes-in-the-united-states